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Implication for health policy/practice/research/medical education:
According to global population ageing, age-related urinary tract cancers are expected to increase in the near future despite 
improved primary prevention, early detection and more efficient treatment.
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Important declines have been observed in urological cancer-related mortality in recent 
decades, mainly due to improvements in treatments of prostate cancer, less exposure to 
tobacco smoking as well as occupational carcinogens of kidney and bladder. However, 
because of global population ageing, age-related urinary tract cancers are expected to increase 
in the near future despite improved primary prevention, early detection and more efficient 
treatment. In this article, renal cell carcinoma (RCC), kidney transplantation, cancer and 
acute kidney injury (AKI), lung cancer and chronic kidney disease (CKD), breast cancer, 
prostate cancer, cervix cancer and brain cancer and their associations with kidney function 
and structure have been discussed. In conclusion, kidney and cancers have interaction with 
each other. Kidney carcinoma can be metastasizing to other organs as well as other cancer to 
kidney. Therefore, it is recommended to consider the potential effect of kidney functions and 
interaction with other cancers in each malignancy. 
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Introduction
Important declines have been observed in urological 
cancer-related mortality in recent decades, mainly due 
to improvements in treatments of prostate cancer, less 
exposure to tobacco smoking as well as occupational 
carcinogens of kidney and bladder (1). However, because 
of global population ageing, age-related urinary tract 
cancers are expected to increase in the near future despite 
improved primary prevention, early detection and 
more efficient treatment (1). Active surveillance from 
renal failure and cancer patients could also  be declined 
the mortality from these diseases (2). In addition, 
approximately 2% to 5% of all kidney cancers may 
originate from inheritance, with about 10 potential cancer 
susceptibility to increase the risk of renal cancer, with 
red flags of multiplicity of tumors, unusual or pathogenic 
pathology or early age of onset (3). On the other hand, 
the involvement of kidney with other tumors may present 
as isolated solitary lesions which is not an end-stage renal 
disease (ESRD), that is sometimes the first and only site 
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of metastatic involvement in patients (4). Primary tumors 
that typically metastasize to the kidney are located in the 
lungs, breasts, esophagus and colon and melanoma.
In the following paragraphs, renal cell carcinoma (RCC), 
kidney transplantation, cancer and acute kidney injury 
(AKI), lung cancer and chronic kidney disease (CKD), 
breast cancer, prostate cancer, cervix cancer and brain 
cancer and their associations with kidney function and 
structure have been discussed. 
Materials and Methods
For this review, we used a variety of sources including 
PubMed/Medline, EBSCO, EMBASE, Web of Science, 
Google Scholar, Scopus and directory of open access 
journals (DOAJ). The search was conducted by using 
combinations of the following keywords and/or their 
equivalents; end-stage renal disease, renal cell carcinoma, 
kidney transplantation, cancer, acute kidney injury (AKI), 
lung cancer, chronic kidney disease, breast cancer, prostate 
cancer, cervix cancer, brain cancer, renal transplantation, 
renal replacement therapy and adenocarcinoma.
Renal cell carcinoma and kidney function
RCC, named also as hypernephroma or Grawitz’s tumor 
and the most prevalent tumor affecting on adults’ kidney, 
responsible for at least 80%–90% of primary malignancies 
of renal cancers in adults (5), is the eighth most common 
cancer among US adults (5) and 2% of all cancers (6). In 
fact, RCC is the seventh and ninth most common cancer 
worldwide among men and women, respectively (7). 
The median age for diagnosis of RCC is around 65 years 
(2). In addition, there are different associated genetic 
factors related to increasing incidence rates of RCC such 
as hereditary papillary renal cancer, von Hippel-Lindau 
disease and tuberous sclerosis (8). Therefore, more 
specialized follow-up is required, especially for patients 
with ESRD and von Hippel-Lindau disease (9). Moreover, 
RCC may have an unpredictable time course, having 
recurrence-free intervals even up to 30 years. Thus, 
prolonged of follow-up is needed (10). Furthermore, 
there are many risk factors of RCC (11) such as tobacco 
use (12) and exposure to some environmental factors 
like cadmium, asbestos, thorium dioxide and petroleum 
products; therefore, some professions are at higher risks 
such as leather tanners, shoe workers as well as asbestos 
workers (11). There are also other risk factors including 
obesity, hypertension and long-term administration of 
analgesics, especially among those containing phenacetin 
(12).
The most common diagnosis among patients who were 
referred with neurologic complications of systemic 
malignancy could be brain metastases (12). In addition, 
brain metastasis was prevalent in patients with lung 
carcinoma and renal carcinoma but not in breast 
carcinoma (12). Moreover, It is reported that Sunitinib 
could be effective and safe to considerable inhibition 
of brain metastasis with no important adverse effect in 
patients with brain metastases from RCC (13). It should 
be mentioned that brain metastases are not rare in RCC, 
even in the patients with a history of nephrectomy even 10 
years before presentation (14).
Renal transplantation and kidney cancers
It is believed that kidney transplantation is now a gold 
standard treatment for ESRD (15). Kidney transplantation 
recipients have shown higher incidence rates of 
malignancies in recent decades because of increasing 
survival rates of these patients (16,17). 
Malignancy is one of the leading causes of death in the 
recipients of kidney transplantation. The prevalence 
of cancer has increased by twofold to threefold among 
kidney transplant recipients compared with the general 
public. This risk growth is not proportionate among all 
types of cancer though, while the prevalence of some kinds 
of cancers will not increase (breasts, prostate, ovary, brain 
and cervix) some other types increase (lungs, colon, liver, 
lymphoma, melanoma, and non-melanoma skin cancers). 
Carcinoma related mortality rate is also higher among the 
recipients of kidney transplantation in comparison with 
the general public. Patient, transplantation, and drugs are 
effective factors in the increased risk of cancer following 
kidney transplantation. Immunosuppressive drugs are the 
most important risk factor as they decrease immunologic 
control of viral-oncologic infections and immune-
surveillance. Although it is an assumed fact that increased 
immunosuppressive dosage is associated with an increased 
risk of cancers secondary to kidney transplantation, the 
disruptive effects of immunosuppressive agents are not 
fully known yet (18). 
Acute kidney injury in cancers
Cancer patients may have the complication of AKI, 
through renal infiltration by malignant cells or metabolic 
disturbances or drug-induced toxicity or sepsis, which is 
important for increasing morbidity and mortality rates as 
well as potential effect on the cancer treatment through 
decreasing chemotherapy dosage or contradiction with 
the cancer treatment (19). In fact, approximately 10 to 
50 percent of cancer patients may experience AKI whom 
about 10 to more than 30% of them might need renal 
replacement therapy (RRT) during their hospitalization in 
intensive care unit (ICU) (20,21). In addition, melanoma, 
breast, lung, esophagus and colon cancers are the most 
common malignancies that could metastasize to kidney, 
leading to large, solitary mass lesions (22). 
Lung cancer and kidney
Non-small cell lung cancer can be metastasizing to kidney 
(23). In addition, it has been confirmed that lung cancer 
and CKD may have a similar course and survival in 
comparison with the patients with lung cancer without 
CKD, which it means that these two diseases could receive 
the same benefit from treatment (24). However, it has 
also approved that CKD could not be an independent 
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risk factor for survival in patients with lung cancer (25). 
Moreover, progressive renal failure was observed in 
patients with lung adenocarcinoma (26). 
In spite of great advances in the care non-small cell lung 
cancer (NSCLC) tumor, 5-year survival rate of NSCLC is 
still less than 15%. More than one-third of NSCLC patients 
are diagnosed with distant metastasis because of failure of 
diagnosis in preliminary stages. Main factors endangering 
a patient’s life originate from local signs of tumor and 
complications from distant metastasis of NSCLC. The 
most common site of hematogenous metastasis is brain, 
followed by bone, liver, adrenal gland and the lung. Renal 
parenchymal metastasis is fairly uncommon. Kidney 
metastases usually do not have clinical symptoms and 
most patients do not have hematuria or azotemia (27). 
Based on the findings, metastatic kidney tumors are 
most often found in the cortical area near the glomerular 
vasculature and rarely spread to the urothelial tissue, 
thereby, the microscopic hematuria incidence is between 
12%-31%.
Since kidney blood flow comprises 20% of cardiac output, 
the kidneys are likely to be susceptible to blood metastasis. 
Although kidney metastasis from NSCLC is routinely 
observed in autopsy, clinical diagnosis of isolated 
metastasis to the kidneys is relatively rare. NSCLC renal 
localization is extremely uncommon. Most often, kidney 
metastasis is either part of a diffused disease or bilateral 
renal metastasis. Therefore, isolated kidney metastasis 
from NSCLC is particularly rare (28).
Breast cancer and kidney
Breast cancer metastasis is common in brain, lung, bones 
and liver bur rarely kidney (29). However, it is possible that 
metastasis of breast cancer leads to a solitary renal mass by 
extending into the renal vein, resulting in a primary renal 
tumor (29). Therefore, histopathological examinations 
of kidney are suggested in breast cancer patients, due 
to the fact that in these patients appropriate systematic 
treatment is better than nephrectomy (29). In addition, 
although metastasis to breast is rare, however, there is 
some evidence that renal cell cancer was metastasizing to 
breast mass (30).
Prostate cancer and kidney 
Prostate cancer is the second most common cancer in 
men, as well as, the second most common cause of death 
from cancer in men. Prostate carcinoma comprises 15% of 
all men’s cancers in developed countries and 4% of men’s 
cancers in developing countries. Typically, prostate cancer 
metastasizes to the bone, lungs, and liver and locally 
invades the seminal vesicles, bladder, rectum, and regional 
lymph nodes (31). 
However, renal mass lesion should be considered in 
primary tumor metastasis, especially among the left size 
localized patients (32). Theoretically, malignancy can 
spread metastasis to any organ. However, prostate cancer 
is often related to pulmonary, hepatic or skeletal and rarely 
kidney (33). Moreover, it should also be considered the 
possibility of prostate metastases to kidney in renal mass 
patients with a history of prostate carcinoma (33).
Kidney is a rare metastatic site in prostate cancer. Since the 
kidney is a highly vascular organ, metastasis infiltration is 
likely due to vascular propagation.
Cervical cancer and kidney 
Approximately 500 000 cases of cervical cancer are detected 
each year worldwide, accounting for almost 5% of all cases 
of diagnosed cancers in the world. A vast majority of these 
cases (over 80%) happens in the developing countries. 
Blood release from tumor cells is a hallmark of end-stage 
cervical cancer. The most common sites of such metastasis 
are the lungs, bones, aorta, and celiac and supraclavicular 
lymph nodes, whereas, kidney metastasis is rare (34).
A very common complication of advanced cervical 
cancer is obstructive nephropathy which one of the 
best techniques for resolving the obstruction could be 
ultrasonography-guided percutaneous neph rostomy 
(PCN) (35). In fact, PCN can recover renal function of 
more than 60% of cervical cancer patients, resulting in 
preventing renal replacement therapy in these patients 
(36). In addition, cervical cancer patients may develop 
hydronephrosis, as a cancer-related or cancer treatment-
related complication, which is associated with higher 
morbidity and worse survival (35).
Conclusion
In conclusion, kidney and cancers have interaction on 
each other. Kidney carcinoma can be metastasizing to 
other organs as well as other cancer to kidney. Therefore, 
it is recommended to consider the potential effect of 
kidney functions and interaction with other cancers in 
each malignancy.
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